Delayed Irreversible Fanconi Syndrome Associated With Vertebral Fracture After Tenofovir Discontinuation.

bone mineral density (bmd) human immunodeficiency virus (hiv) osteoporotic fractures tenofovir alafenamide (taf) tenofovir disoproxil fumarate (tdf)

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jan 2024
Historique:
accepted: 31 01 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

The use of tenofovir disoproxil fumarate (TDF) as an antiretroviral agent has been reported to adversely affect both renal tubules and bone health, leading to pathological fractures. While such an effect is largely reversible, substituting TDF with tenofovir alafenamide (TAF) might result in lower rates of adverse events with the preservation of tenofovir effectiveness. We report a case of a 40-year-old lady with HIV infection who had a vertebral fragility fracture secondary to TDF-associated Fanconi syndrome. The syndrome developed four years after TDF cessation and switching to TAF. Other etiologies for decreased bone mass were excluded, and the diagnosis of Fanconi syndrome was established based on her bone mineral density (BMD) and urine parameters. She was treated conservatively with active vitamin D, calcium, and progesterone/estrogen combination, but her phosphate wasting persisted despite switching to TAF; this likely represents a delayed irreversible effect of TDF on the patient's bone remodeling. This case report highlights the chronic sequelae of TDF therapy and the importance of monitoring for and early detection of renal tubulopathy and osteoporotic fractures in this patient population.

Identifiants

pubmed: 38435900
doi: 10.7759/cureus.53280
pmc: PMC10905307
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e53280

Informations de copyright

Copyright © 2024, Qorban et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Ghofran N Qorban (GN)

Endocrinology, Diabetes, and Metabolism, Dr. Solaiman Fakeeh Hospital, Jeddah, SAU.
Endocrinology, Diabetes, and Metabolism, King Abdulaziz University Hospital, Jeddah, SAU.

Jameelah Alyami (J)

Diabetes and Endocrinology, Dr. Solaiman Fakeeh Hospital, Jeddah, SAU.

Shaza Samargandy (S)

Endocrinology, King Abdulaziz University Hospital, Jeddah, SAU.

Tariq A Madani (TA)

Medicine, King Abdulaziz University Hospital, Jeddah, SAU.

Classifications MeSH